Trial Profile

Phase 2 trial of 186Rhenium Nanoliposomes

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rhenium-186 etidronic acid (Primary)
Indications Glioblastoma
Focus Registrational; Therapeutic Use
Sponsors Cerenome

Most Recent Events

31 Jul 2026 According to the Plus Therapeutics media release, Plus Therapeutics is now called Cerenome.
14 Aug 2020 New trial record
10 Aug 2020 According to a plus therapeutics media release, the company plans to Finalize RNL Phase 2/pivotal trial plan in recurrent glioblastoma in second half of 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com